PensionDanmark Pensionsforsikringsaktieselskab Has $6.54 Million Holdings in Neurocrine Biosciences, Inc. $NBIX

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 11.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,791 shares of the company’s stock after buying an additional 4,131 shares during the quarter. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Neurocrine Biosciences were worth $6,538,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. DJE Kapital AG acquired a new position in Neurocrine Biosciences during the fourth quarter worth $28,000. Geneos Wealth Management Inc. grew its stake in Neurocrine Biosciences by 143.6% during the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. Meeder Asset Management Inc. grew its stake in Neurocrine Biosciences by 651.6% during the fourth quarter. Meeder Asset Management Inc. now owns 233 shares of the company’s stock worth $33,000 after buying an additional 202 shares during the last quarter. Basecamp Wealth Advisors LLC increased its holdings in shares of Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after buying an additional 204 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth approximately $33,000. 92.59% of the stock is currently owned by institutional investors.

Neurocrine Biosciences Trading Up 2.2%

Shares of NASDAQ NBIX opened at $163.41 on Friday. Neurocrine Biosciences, Inc. has a 1 year low of $122.14 and a 1 year high of $186.12. The firm’s 50-day moving average is $168.49 and its 200-day moving average is $147.45. The firm has a market capitalization of $16.61 billion, a PE ratio of 23.96, a price-to-earnings-growth ratio of 0.58 and a beta of 0.39.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 245,088 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $154.33, for a total value of $37,824,431.04. Following the transaction, the director directly owned 511,293 shares of the company’s stock, valued at approximately $78,907,848.69. This trade represents a 32.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $157.65, for a total transaction of $2,364,750.00. Following the sale, the director owned 34,480 shares of the company’s stock, valued at $5,435,772. The trade was a 30.32% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 395,422 shares of company stock valued at $62,448,693. 4.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NBIX. Morgan Stanley boosted their target price on Neurocrine Biosciences from $193.00 to $196.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Guggenheim lifted their price objective on Neurocrine Biosciences from $200.00 to $222.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wedbush increased their target price on Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an “outperform” rating in a report on Monday, August 3rd. Cantor Fitzgerald raised their target price on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Needham & Company LLC lifted their price target on Neurocrine Biosciences from $200.00 to $204.00 and gave the company a “buy” rating in a report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $201.50.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research?driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.